CO5650242A2 - Metodo para tratar hipotiroidismo - Google Patents
Metodo para tratar hipotiroidismoInfo
- Publication number
- CO5650242A2 CO5650242A2 CO05084787A CO05084787A CO5650242A2 CO 5650242 A2 CO5650242 A2 CO 5650242A2 CO 05084787 A CO05084787 A CO 05084787A CO 05084787 A CO05084787 A CO 05084787A CO 5650242 A2 CO5650242 A2 CO 5650242A2
- Authority
- CO
- Colombia
- Prior art keywords
- dose
- treat
- hour
- day
- hypotiroidism
- Prior art date
Links
- 230000037396 body weight Effects 0.000 abstract 3
- 208000003532 hypothyroidism Diseases 0.000 abstract 3
- 230000002989 hypothyroidism Effects 0.000 abstract 3
- 230000007774 longterm Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
1.- Un método para tratar hipotiroidismo en un sujetoadulto que tiene hipotiroidismo, que comprende la administración a largo plazo al sujeto adulto de T3 en una dosis de 0,005-0,03 µg/kg de peso corporal/hora/día efectivo para tratar hipotiroidismo en un sujeto.2.- El método de la reivindicación 1, en donde el T3 es administrado en una dosis de 0,0075-0,02 µg/kg de peso corporal/hora/día.3.- El método de la reivindicación 2, en donde el T3 se administra en una dosis de 0,01-0,015 µg/kg de peso corporal/hora/día.4.- El método de la reivindicación 2, en donde el T3 se administra en una dosis de cerca de 0,01 µg/kg de pesocorporal/hora/día.5.- El método de la reivindicación 1, en donde la dosis diaria de T3 es 8-50 µg.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/364,800 US20040156893A1 (en) | 2003-02-11 | 2003-02-11 | Method for treating hypothyroidism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5650242A2 true CO5650242A2 (es) | 2006-06-30 |
Family
ID=32824502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05084787A CO5650242A2 (es) | 2003-02-11 | 2005-08-25 | Metodo para tratar hipotiroidismo |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20040156893A1 (es) |
| EP (1) | EP1599193A4 (es) |
| JP (1) | JP2006517588A (es) |
| AU (1) | AU2004211961B2 (es) |
| BR (1) | BRPI0407410A (es) |
| CA (1) | CA2515400A1 (es) |
| CO (1) | CO5650242A2 (es) |
| NO (1) | NO20054034L (es) |
| WO (1) | WO2004071432A2 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20110713A1 (it) | 2011-04-29 | 2012-10-30 | Bracco Imaging Spa | Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina |
| ITMI20022394A1 (it) | 2002-11-13 | 2004-05-14 | Bracco Spa | Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche. |
| US10150792B2 (en) * | 2010-11-08 | 2018-12-11 | Synthonics, Inc. | Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients |
| US10695309B2 (en) | 2017-03-31 | 2020-06-30 | Western New England University | Sustained-release liothyronine formulations, method of preparation and method of use thereof |
| US11793981B2 (en) | 2020-05-21 | 2023-10-24 | Equilibrate Therapeutics, LLC | Microneedle device for control of thyroid hormone levels |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3577535A (en) * | 1966-06-29 | 1971-05-04 | Armour Pharma | Treatment of thyroid hormone impairment pharmaceutical compositions containing 3,5,3' -l-triiodothyronine complexes |
| US3477954A (en) * | 1966-06-29 | 1969-11-11 | Armour Pharma | Phosphonium iodide complexes of thyroxine,methods of preparing same,and methods of preparing 3,5,3'-l-triiodothyronine therefrom |
| US3621096A (en) * | 1969-04-03 | 1971-11-16 | Univ North Carolina | Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone |
| US3689669A (en) * | 1970-10-09 | 1972-09-05 | Univ Of North Carolina The | Antidepressant method and composition |
| US3928553A (en) * | 1972-03-23 | 1975-12-23 | Univ New York | Radioimmunoassay method for triiodothyronine and thyroxine |
| US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| GB8613688D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| US5158978A (en) * | 1990-02-05 | 1992-10-27 | British Technology Group (U.S.A.) | Thyroid hormone treatment of acute cardiovascular compromise |
| NO924985L (no) * | 1991-12-30 | 1993-07-01 | Akzo Nv | Thyroaktiv blanding med vedvarende frigjoering |
| US5571840A (en) * | 1993-06-22 | 1996-11-05 | The Regents Of The University Of Michigan | Method for treating central nervous system ischemia |
| US6288117B1 (en) * | 2000-03-23 | 2001-09-11 | North Shore-Long Island Jewish Research Institute | Method for treating congestive heart failure |
| US20020183882A1 (en) * | 2000-10-20 | 2002-12-05 | Michael Dearing | RF point of sale and delivery method and system using communication with remote computer and having features to read a large number of RF tags |
| US20030194437A1 (en) * | 2001-08-14 | 2003-10-16 | Franz G. Andrew | Levothyroxine compositions having unique triiodothyronine Cmax properties |
-
2003
- 2003-02-11 US US10/364,800 patent/US20040156893A1/en not_active Abandoned
-
2004
- 2004-02-06 JP JP2006503412A patent/JP2006517588A/ja active Pending
- 2004-02-06 EP EP04709106A patent/EP1599193A4/en not_active Withdrawn
- 2004-02-06 BR BRPI0407410-6A patent/BRPI0407410A/pt not_active IP Right Cessation
- 2004-02-06 WO PCT/US2004/003620 patent/WO2004071432A2/en active Application Filing
- 2004-02-06 CA CA002515400A patent/CA2515400A1/en not_active Abandoned
- 2004-02-06 AU AU2004211961A patent/AU2004211961B2/en not_active Ceased
- 2004-09-24 US US10/949,722 patent/US20050176829A1/en not_active Abandoned
-
2005
- 2005-08-25 CO CO05084787A patent/CO5650242A2/es not_active Application Discontinuation
- 2005-08-30 NO NO20054034A patent/NO20054034L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0407410A (pt) | 2006-02-21 |
| NO20054034D0 (no) | 2005-08-30 |
| US20040156893A1 (en) | 2004-08-12 |
| CA2515400A1 (en) | 2004-08-26 |
| JP2006517588A (ja) | 2006-07-27 |
| WO2004071432A3 (en) | 2005-03-10 |
| EP1599193A4 (en) | 2007-04-04 |
| NO20054034L (no) | 2005-10-05 |
| AU2004211961A1 (en) | 2004-08-26 |
| EP1599193A2 (en) | 2005-11-30 |
| US20050176829A1 (en) | 2005-08-11 |
| AU2004211961B2 (en) | 2009-04-23 |
| WO2004071432A2 (en) | 2004-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP088123A (es) | Anticoncepcion oral con trimegestona | |
| CO6160321A2 (es) | Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo | |
| CO6150188A2 (es) | Uso de teencteplasa para tratar un ictus isquemico agudo | |
| CO5650242A2 (es) | Metodo para tratar hipotiroidismo | |
| PE20061314A1 (es) | Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo | |
| AR049985A1 (es) | Tratamiento de combinacion para enfermedades malignas no hematologicas | |
| ES2133402T3 (es) | Composiciones, para el tratamiento de la artritis, que contienen fosfonatos y farmacos anti-inflamatorios no esteroideos. | |
| CO2021008988A2 (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
| PE20160195A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
| AR036813A1 (es) | Composiciones farmaceuticas | |
| SV2004001756A (es) | Nueva difenilazetidinona con propiedades fisiologicas mejoraradas, procedimiento para su preparacion, medicamentos que comprenden este compuesto y su uso | |
| ES2570401T3 (es) | Métodos de tratamiento usando dosis únicas de oritavancina | |
| CL2020000491A1 (es) | Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry. | |
| ECSP044986A (es) | Composicion farmaceutica que comprende lumiracoxib | |
| ES2563068T3 (es) | Tratamiento de esclerosis múltiple (MS) con Campath-1H | |
| PE20211199A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| AR065139A1 (es) | Medicamento para el tratamiento de la endometriosis | |
| AR023185A1 (es) | Tratamiento de cancer mejorado con temozolomida | |
| PE20040724A1 (es) | Composicion para la administracion oral de calcitonina | |
| PE20020466A1 (es) | Combinacion de raloxifeno y exemestano para el tratamiento de cancer de mama | |
| CO5611129A2 (es) | Co-terapia con oxazolidinona | |
| AR023399A1 (es) | Metodo para utilizar emamectina para tratar los parasitos de los peces | |
| AR054210A1 (es) | Utilizacion de alfa-1 antitripsina para la preparacion de medicamentos para el tratamiento de la fibromialgia | |
| AR077123A1 (es) | Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica | |
| AR048068A1 (es) | Piperazinas derivadas de urea para el tratamiento de endometriosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |